{"id":"W3204360130","doi":"10.1136/ijgc-2021-002933","title":"ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001371389,0.001248985,0.001407655,0.000437686,0.0002871022,0.0009130295,0.001061817,0.001626244,0.005327635],"category_scores_gemma":[0.001030778,0.0004980787,0.001394438,0.000317815,0.0008649374,0.0008658387,0.0004339131,0.002752298,0.0008762522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008213734,"about_ca_system_score_gemma":0.001026632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009449283,"about_ca_topic_score_gemma":0.003401191,"domain_scores_codex":[0.9996179,0.0002013856,0.00001421236,0.00007677605,0.00003127537,0.00005849482],"domain_scores_gemma":[0.9994546,0.0001007615,0.0001258843,0.0000404371,0.00002688553,0.0002513241],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9197168,0.01757945,0.001891019,0.0008500109,0.001204351,0.00008684348,0.00008523186,0.0008240855,0.006846996,0.0003238625,0.002294295,0.04829712],"study_design_scores_gemma":[0.8890358,0.1047761,0.003062201,0.0000394113,0.0003997661,0.0000849697,0.00002153035,0.0005988825,0.0004920429,0.0001985693,0.001276674,0.00001396782],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843568,0.005098948,0.0006151443,0.0008370802,0.0003970121,0.004336654,0.001148997,0.0001603545,0.003049026],"genre_scores_gemma":[0.9835955,0.002476484,0.002058912,0.001839654,0.0003446655,0.004076584,0.001820805,0.0000276933,0.003759722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005327635,"threshold_uncertainty_score":0.01782274,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02838084312433299,"score_gpt":0.3740461018474168,"score_spread":0.3456652587230838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}